Compound index

Melanocortin Receptor Agonists

Bremelanotide

Also known as PT-141 · Vyleesi

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Class & structure

A 7-amino-acid chain.

Conceptual amino-acid chain · 7 residues in this molecule

How it’s thought to work

Activates melanocortin receptors, including central pathways; receptor activity does not define every clinical outcome.

Molecule → target. A conceptual fit, not proof of a clinical effect.

Key sources

Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.

Related glossary terms